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ABSTRACT 
Artificial metalloenzymes have witnessed increased attention over the last 
decade as a possible solution to unaddressed challenges in synthetic organic 
chemistry. While traditional transition metal catalysts typically only take 
advantage of the first coordination sphere to control reactivity and selectivity, 
artificial metalloenzymes can modulate both the first and second coordination 
spheres. This difference can manifest itself in reactivity profiles that can be truly 
unique to artificial metalloenzymes. This review summarizes attempts to 
modulate the second coordination sphere of artificial metalloenzymes using 
genetic modifications of the protein sequence. In doing so, the review highlights 
successful attempts and creative solutions to address the challenges 
encountered. 
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1. INTRODUCTION 
Biocatalysis has evolved from a field of research that observes the natural 
catalytic properties of enzymes to one that expands the reactivity of existing 
enzymes and creates entirely new enzymes with reactivity never before seen in 
nature. 1  This paradigm shift was largely spurred by advances in molecular 
biology and the development of systematic methods for altering proteins 
properties through iterative rounds of genetic modification (i.e. directed 
evolution).2  Directed evolution efforts have primarily targeted broadening solvent 
tolerance, increasing temperature stability, expanding substrate scope, and 
increasing reaction selectivity (enantio-, diastereo-, regio-, and 
chemoselectivity).3 The catalysts accessed via directed evolution are superb 
catalytic species, capable of providing synthetic methods with superior efficiency 
to those achieved using small molecule catalysts.4 The chief limitation to further 
adoption of biocatalytic processes is the breadth of reactions accessible to this 
catalytic manifold.  
Addressing this limited reaction breadth has become the focus of intense 
interest in the last decade.5 The pursuit of catalytic promiscuity in biocatalysis 
has largely centered on finding new reactions that proceed via mechanisms that 
rely on intermediates that are similar to those of the natural reaction. This is 
perhaps best epitomized in the hydrolase literature where common hydrolases 
are shown to be effective catalysts for Aldol, Michael, and Mannich reactions, 
among many others.6 After the discovery of new reactivity, the promiscuous 
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function can be further optimized via extensive protein engineering. 7  While 
effective, this approach is restricted to reactions that share mechanistic 
similarities with natural reactions. As a consequence, large swaths of non-natural 
reactions are inaccessible via this method. In particular, the wealth of reactions 
catalyzed by transition metals are largely inaccessible. An approach to 
encompass these reactions is to place a transition metal into a protein active site, 
either in the form of artificial metalloenzymes or natural metalloenzymes and 
explore their potential to catalyze reactions that the metal cofactor may catalyze 
independently.  
An early manifestation of this goal was the formation of artificial 
metalloenzymes, where a catalytically active transition metal is selectively 
incorporated into a protein scaffold. In the mid-1970’s Kaiser and Whitesides 
demonstrated that such hybrid catalysts could be formed and provide catalytic 
activity for oxidation and reduction reactions.8,9 Since these seminal reports, 
studies in the field have largely focused on how to selectively introduce different 
transition metal complexes into a variety of protein scaffolds via dative, covalent, 
or supermolecular anchoring while maintaining or enhancing the catalytic activity 
of the metal.10 A complementary approach is to use proteins that have a natural 
affinity for a cofactor capable of catalyzing non-natural reactions in the absence 
of the protein scaffold. Both of these approaches represent only the first-step in 
developing metalloenzyme catalysts capable of catalyzing non-natural reactions. 
In order to create a hybrid that truly benefits from both the protein and transition 
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metal components, the protein component must be genetically engineered for the 
desired traits. While genetic modification of natural enzymes is applied routinely 
both in academia and in industry, the same does not hold true for artificial 
metalloenzymes.11 Perhaps the greatest challenge towards directed evolution of 
artificial metalloenzymes is to maintain catalytic efficiency of the cofactor in the 
presence of unpurified protein samples.12 Indeed, many organometallic cofactors  
are inhibited in the presence of cellular extracts (e.g. DNA, proteins, metabolites, 
lipids etc.). This sets a stringent requirement on the use of purified protein 
samples for the optimization of artificial metalloenzymes. This prerequisite thus 
limits the number of samples that can be screened as parallel protein purification 
is time consuming. This review summarizes the efforts towards the genetic 
optimization of artificial metalloenzymes for catalytic reactivity and selectivity. 
Genetic modifications of protein scaffolds to enable transition metal docking (i.e. 
bioconjugation) have recently been reviewed and will not be further discussed 
herein.10 Our aim is to identify broadly applicable strategies for genetically 
engineering metalloenzymes. Ultimately, these should be applicable toward other 
types of metalloenzymes and thus expand the field from one that looks simply to 
find effective hybrid catalysts to one that aims at exploiting these systems to 
address challenges that neither small molecules catalysts nor enzymes can 
currently address. Two complementary strategies are summarized in this review: 
i) repurposing natural metalloenzymes towards non-natural reactions (Sections 2 
and 6) and ii) introducing an abiotic cofactor within a protein scaffold to generate 
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artificial metalloenzymes (Sections 3-5). Artificial metalloezymes resulting from 
chemically synthesized host protein/peptides (i.e. solid-phase synthesis) have 
been recently reviewed and will not be presented herein.10 The focus of this 
review is set on the genetic strategies for the optimization of the performance of 
(artificial) metalloenzymes. 
2. Natural Metalloenzymes that Catalyze Non-Natural Reactions 
2.1 Cytochrome P450s 
Cytochrome P450s are widespread and powerful enzymes that oxidize 
olefins, heteroatoms, and inert C–H bonds using molecular oxygen or hydrogen 
peroxide as oxidant.13 Essential for this reactivity is the iron porphyrin heme 
cofactor. Aside from effecting oxygenation, iron porphyrins are known to catalyze 
the cyclopropanation of alkenes with diazoesters.14 Arnold was interested in 
exploring the ability of P450s to catalyze carbene transfer reactions.15  In a 
seminal report, P450BM3 was shown to be an effective catalyst for the 
cyclopropanation of styrenes using ethyl diazoacetate (EDA) as a carbene 
source under anaerobic conditions, providing product with low conversion and 
selectivity (5 TTNs).16 A single mutation of the conserved distal threonine (T268), 
hypothesized to facilitate proton transfer in the natural reactivity, to alanine 
(P450BM3-T268A) enabled trans-selective cyclopropanation in high yield and 
enantioselectivity (Figure 1). The cis-diastereomer was accessed preferentially 
using a variant that contained 14 mutations from wild-type (P450BM3-CIS), in 
modest yield and diastereoselectivity but with excellent enantioselectivity (Figure 
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1). Introduction of serine at position T438 (P450BM3-CIS-T438S), improved the 
diastereoselectivity to > 9 : 1 as well as the enantioselectivity and the yield. A 
small library of structurally distinct P450BM3 mutants allowed for selective 
cyclopropanation of a diverse set of styrenes. This library was also effective for 
the insertion of carbenes into N–H bonds.17  Preliminary mechanistic studies 
suggest that Fe(II) is the resting state of the heme-cofactor. This feature presents 
a challenge when attempting to reduce heme from Fe(III) to Fe(II) under 
physiological conditions, as P450s have an elaborate gating mechanism to 
prevent electron transfer in the absence of substrate. Given the low affinity of the 
substrates for the protein’s active site, the desired conformational change is not 
possible.  
 
Figure 1 Repurposing cytochrome P450 as an artificial cyclopropanase under 
anaerobic conditions. The catalytic performance is improved by genetic 
modification of the second coordination sphere of the heme cofactor. While trans-
selectivity requires a single point mutation, the cis-cyclopropanase bears fifteen 
mutations compared to WT P450BM3. P450BM3-CIS-T438S = V78A, F87V, P142S, 
N2
O
EtO
Ph CO2Et
Ph CO2Et
P450BM3-T268A
P450BM3-CIS-T438S
65% yield (3)
323 TTN
99:1 trans/cis
98:2 er
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293 TTN
9:91 trans/cis
98.5:1.5 er
1 2
+
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T175I, A184V, S226R, H236Q, E252G, T268A, A290V, L353V, I366V, T438S, 
E442K. 
 
To facilitate reduction, Arnold explored the impact of heme-ligation on the 
redox potential of the heme-cofactor.18  Remarkably, mutating the cysteine to the 
isosteric serine, shifts the redox potential from -430 mV (E0’ FeIII/FeIIcys) to -293 
mV (E0’ FeIII/FeIIser). The resulting P450BM3-C400S variant, referred to as P411BM3 
(named for the shift in the diagnostic CO Soret band), possesses a redox 
potential well within the range for the biological reductant NADPH (E0’1 = -320 
mV). Furthermore, the P411BM3 has poor oxygenase reactivity thus eliminating 
undesired styrene oxide formation. Finally, the efficiency with which the P411BM3 
effects the desired transformation is roughly four times superior that of the 
P450BM3 (Figure 2a). At high substrate concentrations, the best catalyst 
(P411BM3-CIS-T438S) affected the cis-selective cyclopropanation with over 
67,000 TTNs and selectivity that was nearly identical to that achieved by the 
P450BM3-CIS-T438S variant (90:10 dr, 99% ee). Crystallographic data suggests 
that mutation of the axial cysteine to serine does not have a significant impact on 
the overall fold of the protein (0.52 Å r.m.s. deviation from P450BM3). Introduction 
of the key axial serine mutation into other P450 scaffolds yields catalysts that are 
more effective for cyclopropanation than the parent metalloenzyme.19  
–11– 
	  
 
Figure 2 a) Mutation of the axial cysteine C400 to serine significantly affects the 
reduction potential of the heme moiety and shifts the Soret band from 450 nm to 
411 nm. The repurposed cytochrome P411 has completely lost its 
monooxygenase activity in favor of cyclopropanation activity. b) Activity of various 
axial ligands for styrene cyclopropanation.  
 
The axial mutation was further expanded to include residues that are not 
isosteric with cysteine.20, 21 This modest screening effort led to the identification 
of histidine (i.e. T268A-C400H) as the most efficient artificial metalloenzyme for 
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the cycloproponation of styrene with EDA (Figure 2b). This engineered variant 
was applied to the formal synthesis of levomilnacipran, where T268A-C400H 
provided the precursor cyclopropane in excellent yield and diastereoselectivity, 
but modest enantioselectivity. After three rounds of site-saturation mutagenesis 
targeting residues located within the protein’s active site, a variant (T268A-
C400H-T438W-V78M-L181V, coined Hstar) was identified that provided the 
cyclopropane precursor to levomilnacipran in high yield and excellent 
enantioselectivity, even under aerobic conditions (Figure 3). Gratifyingly and in 
contrast to many biocatalysts, Hstar is a fairly general catalyst furnishing high 
yields and selectivity for an array of substituted acrylamides.22  
 
	  
Figure 3 Directed evolution of the artificial cyclopropanase Hstar for the 
synthesis of a levomilnacipran precursor.  
 
The P411 scaffold is also effective for nitrene transfer reactions. Arnold 
found that P411BM3-T268A could effect benzylic C–H amination on 1,3,5-triethyl 
benzenesulfonylazide 7, albeit in modest yield.23  In contrast to the carbene 
transfer reactivity, Arnold found that P450BM3 based catalysts were inefficient for 
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this type of reactivity. Engineering the protein scaffold to a variant bearing an 
additional 15 mutations from WT-P450BM3 (P411BM3-CIS-T438S) improved the 
yield to nearly 70% yield (430 TON) and excellent enantioselectivity (87% ee) 
(Figure 4). The impact of the active site architecture is critically important when 
considering nitrene transfer reactions in the protein’s active site. Arnold found 
that triethyl benzenesulfonylazide 7 is more effective than triisopropyl 
benzenesulfonylazide 9 despite the lower bond dissociation energy of the later 
substrate (85 kcal/mol compared to 83 kcal/mol). Fasan and coworkers observed 
the opposite trend in subsequent work using other P450s variants (P450BM3-
FL#62), where triisopropyl benzenesulfonylazide 9 was more effective than 
triethyl benzenesulfonylazide 7 (Figure 4). 24  Possible explanations for this 
difference include the differing heme-ligation in the two studies or the differing 
active site architectures of the variants used in each study.   
 
Figure 4 Cytochrome P411BM3- and P450BM3-catalyzed nitrene insertion. 
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Et
Et Et
S N3
O O
P450BM3 Variant
purified protein
Et
Et
NH
S
O O
H Me
P411BM3-CIS-T438S 383 TTNs 73% ee
P450BM3-FL#62 47 TTNs 50% ee
i-Pr
i-Pr i-Pr
S N3
O O
P450BM3 Variant
purified protein
i-Pr
i-Pr
NH
S
O O
Me Me
P411BM3-CIS-T438S 36 TTNs
P450BM3-FL#62 388 TTNs
7 8
9 10
–14– 
E252G, T268A, A290V, L353V, I366V, C400S, T438S, E442K. P450BM3-#FL62 = 
V87A, F81S, A82V, F87A, P142S, T175I, A180T, A184V, A197V, F205C, 
S226R, H236Q, E252G, R255S, A290V, L353V. 
 
The initial reports of P450-catalyzed C–H amination exclusively reported 
amination of weakest C–H bond present in the substrate. Arnold found that the 
strong C–H bonds could be selectively aminated in the presence of weak C–H 
bonds through systematic modulation of the active site architecture.25 Amination 
of the strong homobenzylic C–H bonds can be achieved with di-propyl 
benzenesulfonylazide 11 when a P411 variant containing phenylalanine at 
position I263F is used (97:3 selectivity over benzylic amination) (Figure 5). The 
selectivity can be reversed in favor of the benzylic amination on the same 
substrate using a triple mutant (F87A-T268A-C400S). Such remarkable 
regiodivergency is difficult to achieve with small molecule catalysts and highlights 
the potential of biocatalytic solutions to complement small molecule methods.   
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Figure 5 Cytochrome P411BM3-catalyzed regioselective nitrene insertion. 
P411BM3-CIS-T438S-I263F = V78A, F87V, P142S, T175I, A184V, S226R, 
H236Q, E252G, I263F, T268A, A290V, L353V, I366V, C400S, T438S, E442K. 
 
While the early reports of P450- and P411-catalyzed C–H amination used 
relatively rigid sulfonylazides as substrates; Fasan found that more flexible 
carbonazidates can be converted to oxazolidinones in modest yield using 
P450BM3-FL#62. 26  A variety of carbonazidates were effective substrates 
providing between 6 and 100 turnovers albeit with low enantioselectivity. Ease of 
synthesis opened the ability to explore the mechanism of enzyme catalyzed 
amination reactions. Mechanistic studies using cis- and trans-homoallyl 
carbonazidates (14 and 15 respectively) show isomerization to the trans-
oxazolidinone 16 suggesting that the reaction proceeds via C–H abstraction to 
generate a long-lived allylic or benzylic radical followed by radical recombination 
(Figure 6). Furthermore, kinetic isotope studies suggest C–H abstraction to be 
rate-limiting.  
 
Figure 6 Mechanistic studies for the amination of C–H bonds catalyzed by 
P450BM3-FL#62 suggest a long-lived allylic or benzylic radical.  
O
O N3
Ph
O
O N3
Ph
P450BM3-FL#62
O NH
O
Ph
O NH
O
Ph
not observed
or
only observed
product
14
15
16
–16– 
 
Serine-ligated P411BM3 species are also capable of catalyzing 
intermolecular nitrene transfer reactions. Arnold found that tosyl azide 18 cand 
amidate sulfides under P411BM3-catalysis to provide sulfimides in modest yield 
(Figure 7).27  The architecture of the active site is essential for catalysis in 
intermolecular nitrene transfer. In unoptimized active sites, the dominant product 
was the reduction of the azide to the corresponding sulfonamide. It is believed 
that this reduction occurs via electron transfer from the reductase domain of the 
P411 to the iron-nitrenoid. In the presence of an optimized active site, 
sulfimidation became competitive with nitrenoid reduction. Hammett studies 
revealed a strong correlation between sulfide electronics and rate of 
sulfimidation, where electron-rich sulfides were amidated faster than electron 
neutral sulfides.  
 Sulfimidation served as a gateway to the more challenging alkene 
aziridination (Figure 7).28 While protein scaffolds identified in the sulfimidation 
study provided only traces of aziridine, introduction of I263F into the active site 
provided a substantial amount of aziridine, albeit in modest enantioselectivity. 
After two rounds of site-saturation mutagenesis to target residues in the active 
site, a variant was identified that provides aziridines in excellent 
enantioselectivity. In contrast to sulfimidation, where the substrate electronics 
largely dictate the substrate scope, the optimized aziridination catalyst tolerates 
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an array of alkenes where electronics have little effect on the reaction efficiency 
and selectivity.   
 
Figure 7 Sulfimidation- and aziridination-catalyzed by evolved cytochrome 
P411BM3 variants. 
 
2.2 Myoglobin Catalyzed Reactions 
Myoglobin is a heme protein that serves as an oxygen carrier in mammals 
with no catalytic function. With respect to heme binding, myoglobin is structurally 
related to peroxygenases where the iron heme is ligated by a histidine residue. 
Despite these similarities, myoglobin is less efficient than peroxidase in effecting 
oxidations.29 This is attributed to the lack of a substrate binding cleft and the 
poorly positioned proximal histidine required to generate compound I.  Hayashi 
hypothesized that the absence of a binding cleft could be overcome by replacing 
the polar carboxylates of the heme with non-polar aromatic groups. 30  By 
extracting the cofactor and reconstituting with a “double-winged cofactor”,  
Hayashi achieved superior reactivity for the oxidation of 2-methoxyphenol. This 
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improvement was traced back to increased affinity for the substrate (decrease in 
Km). To increase the reactivity of the complex, Hayashi explored mutation of the 
proximal histidine. By mutating histidine 64 to aspartic acid (H64D), the 
peroxidase activity was increased for myoglobin Figure 8. Further replacement 
of the natural cofactor with the doubled-winged cofactor increased the peroxidase 
activity by nearly 400 fold.   
 
 
Figure 8 Repurposing myoglobin into a peroxygenase by chemogenetic 
optimization.  
Imidazole-ligated iron-porphyrins are known to be efficient small molecule 
catalysts for carbene transfer reactions.31 Fasan found that, in the presence of 
EDA and various primary and secondary anilines, myglobin is able to effect 
carbene insertion into N–H bonds with efficiencies that surpass hemin alone 
(Figure 9).32 As mentioned above, one drawback of WT myoglobin is its lack of 
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binding cleft. An active site can be carved out through mutation of the conserved 
distal histidine to valine (H64V) and mutation of a flanking valine to alanine  
(V68A). The improved catalyst provides excellent turnovers (up to 7,500 TTN). In 
addition, it is also effective in coupling substituted styrenes with EDA to provide 
trans-cyclopropanes in high yield (> 46,000 TTN) and exquisite 
diastereoselectivity and enantioselectivity (Figure 9). 33  Mechanistic studies 
suggest that the cyclopropanation occurs via an electrophilic iron-carbenoid 
intermediate. This latter closely resembles the intermediate proposed for small 
molecule catalysts.  
In addition to N–H insertion and cyclopropanation, myoglobin also 
catalyzes carbene insertion into S–H bonds.34 In this case however, the best 
variant for S–H insertion is L29A-H64V. This variant provides activity for a range 
of substituted aromatic and aliphatic thiols, a feat not possible in the N–H 
insertion or cyclopropanation chemistry. Furthermore, sterically bulky 
cyclohexane, tert-butyl, and benzyl substituent diazoesters all provide excellent 
yields. A brief screen of active site mutants provided a variant (F43V) that is 
capable of rendering this transformation asymmetric. 
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Figure 9 Myoglobin-catalyzed carbene insertion into N–H bonds, alkenes, 
and S–H bonds.  
 
Much like P450s, myoglobin is also able to effect C–H amination via 
nitrene transfer, albeit in modest yield.35 Mutation of the conserved distal histidine 
to valine (H64V) provides a modest increase in catalyst activity. Through 
modification of the active site, the enantioselectivity of the insertion can be 
modulated. In general, myoglobin is less effective for reactions involving nitrenoid 
species than carbenoid species. To address this issue, Fasan explored 
exchanging the heme cofactor by Mn and Co hemin species that are known to be 
more effective for amination under organic conditions. Unfortunately, they were 
less effective that Fe-hemin. 
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Some of the best-studied artificial metalloenzymes take advantage of the 
strong non-covalent interaction between streptavidin (Sav) and biotinylated metal 
complexes. 36  The seminal report by Whitesides demonstrated that 
[Rh(NBD)(Biot-1)]  ⊂  avidin (Avi) could effect the hydrogenation of N-
acetamidoacrylic acid 22 to (R)-N-acetamidoalanine 24 in modest 
enantioselectivity (up to 41%).9 (⊂ indicates supramolecular inclusion of the metal 
cofactor into the host protein.) Ward re-examined this reaction using streptavidin 
rather than avidin as the host protein. Streptavidin, like avidin, is a 
homotetrameric protein with high affinity for biotin (Ka > 1013 M-1).37 It differs from 
avidin in its dielectric constant (pl: 6.2 for Sav versus pl: 10.4 for Avi) and ease of 
recombinant expression in E. coli. Upon switching from Avi to Sav, under 
otherwise similar reaction conditions, Ward and coworkers found that 
[Rh(COD)(Biot-1)]  ⊂  WT Sav  furnished (R)-N-acetamidoalanine 24 in 
quantitative yield and 92% ee (Figure 10). 38  The hybrid catalyst was also 
effective for the reduction of N-acetamidocinnamic acid 23 to (R)-N-
acetamidophenylalanine 25 in 84% conversion and 93% ee.39 
–22– 
		  
Figure 10 Artificial hydrogenase resulting from incorporation of a 
biotinylated Rh-diphosphine moiety within Sav variants.  
 
Ward and coworkers identified that modifying the amino acid spacer that 
links the metal to the biotin anchor can drastically vary the chemical environment 
in which the metal cofactor resides within streptavidin’s “active site”. More subtle 
fine-tuning can be achieved via genetic modification.39, 40  For example, site 
saturation at position S112 with [Rh(COD)(Biot-L)] provided two genetic mutants 
S112G and S112A which provided increased enantioselectivity for the (R)-
enantiomer of N-acetamidocinnamic 23 and N-acetamidophenylalanine 24 
AcHN CO2H
AcHN CO2H
Ph
or
Ligand (1.0 mol %)
[Rh(cod)Cl2]2 (0.9 mol %)
Host Protein (0.33 mol %)
H2 (5 bar), MES Buffer
Me
AcHN CO2H
AcHN CO2H
Ph
or
22
23
24
25
Entry Ligand Protein % ee 24 % conv 24 % conv 25% ee 25
1 Biot-L WT Avi 37 (S) 90 - -
2 Biot-L WT Sav 92 (R) Quant. 93 (R) 84
3 Biot-L Sav S112G 96 (R) Quant 94 (R) 77
4 Biot-4meta-L Sav S112K 63 (S) Quant 88 (S) 89
5 Biot-(R)-Pro-L Sav S112W 95 (S) Quant 95 (S) Quant
(+)-Biotin N
PPh2
PPh2
Biot-L
NH(+)-Biotin
N
O
PPh2
PPh2N
PPh2
PPh2
O
N
(+)-Biotin H
Biot-(R)-Pro-L Biot-4meta-L
HN NH
S
H
O
H
O
(+)-Biotin
–23– 
(Figure 10). However, attempts to access the opposite enantiomer were 
unproductive using genetic modification alone. Testing 18 different chemical 
linkers provided two chemical linkers [Rh(COD)(Biot-4meta-L)] and 
[Rh(COD)(Biot-(R)-Pro-L)] that yielded preferentially the (S)-enantiomer. 41 
Screening with Sav isoforms led to the identification of [Rh(COD)(Biot-(R)-Pro-
L)] ⊂ S112W that afforded both products in quantitative yield and 95% ee 
(Figure 10). 
A subsequent study by Reetz explored a directed evolution strategy to 
optimize [Rh(COD)(Biot-L)] ⊂ Sav for the enantioselective reduction of methyl-N-
acetamidoacrylate. 42  Unfortunately, complications in protein expression in 
purification required the use of small site-saturation libraries rather than large 
error-prone libraries. Reetz selected positions in the close proximity of the active 
site (i.e. N49, L110, S112, L124). In the initial round, S112G was identified as a 
positive mutation affording product in 35% ee in favor of the (R)-enantiomer 
(compared to 23% ee for WT Sav). A second round of mutagenesis furnished a 
double mutant N49V-S112G that provided the product in 54% ee. When the 
N49V was evaluated alone it provided the best enantioselectivity in the study 
(65% ee). After two rounds of mutagenesis, the opposite enantiomer (S)-(N)-
acetamidoalanine-methylester could be obtained in 7% ee in the presence of  
[Rh(COD)(Biot-L)] ⊂ Sav N49H-L124F.  
Building on the hydrogenation of alkenes, Ward explored biotinylated 
aminosulfonamide-ligated piano stool complexes as catalysts for transfer 
–24– 
hydrogenation of ketones.43 Mechanistically, transfer hydrogenation is distinct 
from classical hydrogenation as that the substrate does not coordinate to the 
metal center. Instead, the reaction is believed to proceed via a concerted 
transition state whereby the hydride is delivered from the metal with a 
concomitant proton delivery from the amine ligand. A family of racemic-at-metal 
N-sulfonamide-1,2-ethylenediamine complexes where prepared from common 
Rh, Ir, and Ru piano stool complexes and were screened against streptavidin 
isoforms. Biotinylation at the para-position of the sulfonamide universally 
provided more reactive complexes. Additionally, arene-capped ruthenium 
complexes provided the highest yields. The capping arene substantially impacts 
the enantiopreference of the reaction with [(η6-benzene)Ru(Biot-p-L)Cl] and [(η6-
p-cymene)Ru(Biot-p-L)Cl] favoring the opposite enantiomers. This effect is most 
pronounced when combined with genetic mutations. For example, in the 
reduction of p-methyl acetophenone [(η6-benzene)Ru(Biot-p-L)Cl] ⊂  WT Sav 
provides product in 89% ee for the (R)-enantiomer while  [(η6-p-cymene)Ru(biot-
p-L)Cl] ⊂ WT Sav provides the same product but in only 29% ee (R). When the 
same reaction are run with S112A, [(η6-benzene)Ru(biot-p-L)Cl] ⊂  S112A 
provides product in 91% ee favoring the (R)-enantiomer while [(η6-p-
cymene)Ru(Biot-p-L)Cl]  ⊂  S112A now provides 41% ee (R). This 
enantiopreference can be inverted when lysine is used in place of alanine: [(η6-
benzene)Ru(Biot-p-L)Cl] ⊂ S112K provides product in 10% ee in favor of the 
(S)-enantiomer while [(η6-p-cymene)Ru(Biot-p-L)Cl] ⊂ S112A provides 63% ee 
–25– 
(R). It is thought that the presence of cationic residues in close proximity the 
metal center may change the interaction responsible for enantioselectivity. When 
greasy residues are close to the metal, C–H···π interactions are may be 
responsible for selectivity. This interaction is likely overruled in favor of cation···π 
interactions when lysine is in close proximity to the active site. A crystal structure 
of the streptavidin bound metal complex revealed that residues K121 and L124 
are in close proximity of the metal center. 
In the initial report, acetophenone derivatives were the only substrates to 
provide high enantioselectivity. Selectivity for dialkyl ketone reduction was 
addressed using iterative rounds of site saturation mutagenesis (Figure 11).44 
Building on the observation that the capping arene can favor different enantio-
preference, Ward conducted site-saturation mutagenesis on [(η6-p-
cymene)Ru(Biot-p-L)Cl] and [(η6-benzene)Ru(Biot-p-L)Cl] with 4-phenyl-2-
butanone. To accelerate the screening process, the streptavidin mutant was 
extracted from crude cell extracts using biotin-sepharose beads. Importantly, 
when Sav is present in excess, the sepharose-bound biotin only occupies one 
biotin-binding site, leaving the other three sites available for catalysis. It was 
quickly identified that the S112A and S112K variants favored the opposite 
enantiomers with both arene-capping groups but with modest enantioselectivity. 
When these mutation were coupled with site saturation libraries at position K121 
and L124, substantially improved enantioselectivities were achieved. For 
example,  [(η6-p-cymene)Ru(Biot-p-L)Cl] ] ⊂ S112A-K121T provided 88% ee 
–26– 
favoring the (R)-enantiomer, while [(η6-p-cymene)Ru(Biot-p-L)Cl] ] ⊂  S112K-
L124T favored the (S)-enantiomer in modest enantioselectivity (26% ee). The 
enantioselectivity for the (S)-enantiomer can be improved to 72% ee with [(η6-
benzene)Ru(Biot-p-L)Cl]  ⊂  S112A-L121N. Interestingly, a single mutation to  
[(η6-benzene)Ru(Biot-p-L)Cl] ⊂ S112A-L121W favors the (R)-enantiomer in 84% 
ee. Collectively, this study suggests the importance of optimizing the genetic 
component of the artificial metalloenzymes for selectivity. 
 
 
Figure 11. Evolutionary path for the most highly selective artificial transfer 
hydrogenase variants for the reduction of 4-phenyl-2-butanone 26.   
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The reduction of alkenes and ketones using artificial metalloenzymes 
complements enzymes that are commonly used for industrial transformations 
(enoate reductases and ketoreductases). 45  Far less explored are the imine 
reductases, which have only recently been discovered.46 In contrast, transfer 
hydrogenation has long been known to effect the enantioselective reduction of 
imines. Using [Cp*Ir(Biot-p-L)Cl] ⊂ WT Sav, the hydrogenation of cyclic imines 
could be effected in quantitative yield and modest enantioselectivity (57% ee 
(R)).47 Genetic optimization provides enhanced selectivity: [Cp*Ir(Biot-p-L)Cl] ⊂ 
S112A affords the (R)-product in 91% ee with over 4000 turnovers (Figure 12). A 
single point mutation with [Cp*Ir(Biot-p-L)Cl]  ⊂  S112K affords the opposite 
enantiomer in 78% ee in favor of the (S)-enantiomer.  
 
 
Figure 12. Reduction of dehydrosalsolidine 28 to salsolidine 29 using Sav-Based 
artificial imine reductase either with purified samples or with cell lysates pre-
treated with diamide. 
 
In order to upgrade the enantiopurity of the amine, the artificial imine reductase 
may be coupled to an amine oxidase (monoamine oxidase, MAO).48 In this 
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cascade, the highly selective MAO oxidizes selectively the (R)-amine back to the 
imine, to ultimately afford enantiopure (S)-amine (Figure 13). This approach 
provides an elegant solution the challenge of combining biocatalytic processes in 
tandem with small molecule transition metal catalysis. In general, it is understood 
that transition metals and enzymes suffer from mutual inhibition. 49  By 
compartmentalizing the organometallic cofactor within a protein scaffold, 
deactivation is avoided. Furthermore, this allows the two reactions to be run in a 
single phase, rather than relying on a multiphase system.50  
 
 
Figure 13.  Artificial transfer hydrogenase run in cascade with a selective mono-
amine oxidase affords enantiopure (R)-cyclic amines.  
 
A challenge for ArMs is to overcome the loss of activity resulting from 
placing the metal in a protein active site. In the case of the imine reductase, the 
free metal cofactor is roughly 20x more active than the ArM in a WT-Sav 
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(compare kcat 21 min-1; Km 34 mM to kcat 1 min-1; Km 5 mM for the free cofactor 
and [Cp*Ir(Biot-p-L)Cl]  ⊂ WT Sav). 51 Ward hypothesized that charged residues 
within the active site might decrease the greasy substrate’s affinity for the active 
site. To address this challenge, hydrophobic residues were sequentially 
engineered into the active site to diminish the polarity of the pocket. Introduction 
of alanine residues at S112 and K121 (S112A-K121A) provided a substantial 
improvement in catalytic efficiency as reflected by an increase in kcat = 24 min-1 
and decrease in Km = 15 mM. Collectively, these observations suggest that 
engineering the active site can increase the activity of the metal center without 
impacting direct metal coordination. 
 
 
Figure 14. Genetic engineering of residues within the biotin-binding vestibule 
allows to significantly improve the catalytic efficiency of an artificial imine 
reductase based on the biotin-streptavidin technology. Reproduced from ACS 
with permission.52 
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ABSTRACT: Artiﬁcial metalloenzymes enable the engineering of
the reaction microenvironment of the active metal catalyst by
modiﬁcation of the surrounding host protein. We report herein
the optimization of an artiﬁcial imine reductase (ATHase) based
on biotin−streptavidin technology. By introduction of lipophilic
amino acid residues around the active site, an 8-fold increase in
catalytic eﬃciency compared with the wild type imine reductase
was achieved. Whereas substrate inhibition was encountered for
the free cofactor and wild type ATHase, two engineered systems
exhibited classical Michaelis−Menten kinetics, even at substrate
concentrations of 150 mM with measured rates up to 20 min−1.
KEYWORDS: artiﬁcial metalloenzymes, imine reduction, transfer hydrogenation, biotin−streptavidin technology, genetic optimization,
saturation kinetics
■ INTRODUCTION
Artiﬁcial metalloenzymes result from incorporation of an
organometallic catalyst precursor within a host protein.1−10 In
analogy to natural metalloenzymes, both the metal coordination
and the substrate-binding sphere around the catalytic site can
be deﬁned and are amenable to optimization. In the past 10
years, we and others have relied on the biotin−(strept)avidin
technology for the creation of artiﬁcial metalloenzymes.
Artiﬁcial metalloenzymes oﬀer new opportunities to improve
catalytic eﬃciency and selectivity. For this purpose, both
chemical modiﬁcation of the ﬁrst coordination sphere and
mutation of the host protein (i.e., the reaction environment)
can be used to optimize the performance of the artiﬁcial
metalloenzyme.11 Although highly enantioselective artiﬁcial
metalloenzymes have been reported for a variety of trans-
formations, they often display lower activity than the “protein-
free” metal cofactor.
To overcome this challenge, approaches relying on ﬁne-
tuning of the ﬁrst or second coordination sphere around the
metal may be envisaged. We recently described ﬁrst
coordination sphere engineering approaches whereby a
biotinylated catalyst precursor was activated upon incorpo-
ration within streptavidin. This was achieved thanks to the
introduction of a coordinating amino acid capable of binding
and activating the artiﬁcial cofactor.12,13
Herein, we present our eﬀorts to improve catalytic eﬃciency
by genetically ﬁne-tuning the reaction environment in direct
proximity of the metal catalyst in an artiﬁcial imine reductase
based on biotin−streptavidin technology, Scheme 1.
■ RESULTS AND DISCUSSION
With the aim of quantifying the eﬀect of streptavidin isoforms
(hereafter, Sav) on the catalytic performance of the biotinylated
d6 piano stool complex [Cp*Ir(biot-p-L)Cl], we set out to
determine the saturation kinetic behavior for the asymmetric
transfer hydrogenation of 1-methyl-3,4-dihydroisoquinoline 1
to the corresponding enantioenriched amine 2 (Scheme 1),
striving for a higher catalytic eﬃciency14 rather than an
improved enantioselectivity.15,16
As a starting point, we determined the kinetic proﬁles for the
isolated catalyst precursor [Cp*Ir(biot-p-L)Cl] as well as for
the artiﬁcial metalloenzyme resulting from its incorporation
within WT Sav, Figure 2 and Table 1 (see the Supporting
Information, SI, for details). As can be appreciated from these
data, compared with the free [Cp*Ir(biot-p-L)Cl] cofactor, the
artiﬁcial metalloenzyme based on WT Sav displays a 20-fold
decrease in rate, as reﬂected by kobs and kcat, respectively (21 ±
7 vs 1 ± 0.1 min−1), accompanied by a decrease in KM (34 ± 16
vs 5.0 ± 1.6 mM). In addition, both systems suﬀer from
substrate inhibition (Ki = 45 ± 20 vs 131 ± 27 mM).
17 Similar
inhibition eﬀects have been reported for the transfer hydro-
genation of carbonyl compounds.18−20 Because the initial rates
are determined at low conversion, we speculate that the binding
of a second substrate molecule in the active site of the ATHase
is responsible for the observed rate decrease, rather than
product or CO2 inhibition.
21 A possible explanation for the
inhibition of the free metal cofactor might be found in the
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Metal coordination is another important feature when considering methods 
to active artificial metalloenzymes. When the metal is linked to biotin through the 
η6-arene or η5-cyclopentadiene ligand, rather than the aminosulfonamide ligand, 
a less active metal complex for transfer hydrogenation of imines is formed. Ward 
hypothesized that coordination of histidine residues to the metal moiety could 
rescue the activity.53 When histidine was introduced at S112 (e.g. S112H), the 
conversion of the reaction increases 10 fold over the wild-type complex to 
provide in quantitative yield and 55% ee (S)-salsolidine 29. Interestingly, when 
histidine was introduced at position K121 (K121H), the enantioselectivity is 
inverted, providing in quantitative yield and 79% ee (R)-salsolidine 29. Evaluation 
of crystal structures of the two variants support that the metal adopts very 
different orientations within the chiral biotin-binding vestibule depending on the 
position of the histidine residue, potentially accounting for the opposite 
enantioselectivities. While, in general, metalloenzymes rely on genetic 
modification of the second coordination sphere, this study suggest that genetic 
optimization of the first coordination sphere can be used to enhance both 
reactivity and the selectivity of ArMs.  
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Figure 15 Activation of latent ArMs by coordination to a histidine residue affords 
artificial imine reductases. The position of the coordinating residue determines 
the enantiopreference of the reduction. 
 
The concept of protein coordination for increased reactivity was applied to 
the development of an artificial metalloenzyme for Rh(III)-catalyzed C–H 
activation of amides to provide dihydroisoquinolones, (Figure 16).54 With such 
catalytic systems, all three available coordination sites of the piano stool moiety 
are required for the reaction to proceed. Therefore opportunities for exogenous 
stereocontrol are limited. Ward and Rovis found that, in the presence of WT Sav, 
a biotinylated {Cp*Rh}-moiety provided enantioenriched product, but in low yield. 
Building on the fact that electrophilic C–H activation requires a base, often a 
carboxylate, to facilitate the C–H activation event, aspartate and glutamate 
residues were engineered in close proximity to the metal. When aspartic acid 
was introduced at K121D, the productivity was enhanced. The most active 
variant, N118K-K121E, provided a nearly 100-fold increase in activity by 
comparison to WT Sav. When combined with the sterically bulky tyrosine at 
position S112, a mutant (i.e. S112Y-K121E) was found that could provide high 
yield and enantioselectivity for the desired product. This represented the first 
example of a enantioselective Rh(III) C–H activation process and the first 
example of placing a mechanistically essential residue on the a protein scaffold 
of an artificial metalloenzyme.   
–32– 
 
Figure 16 An artificial benzannulase results from incorporation of a biotinylated 
Cp*Rh(III) moiety within Sav. Engineering a basic residue at position 121 leads to 
a hundred-fold increase in rate. 
 
Artificial metalloenzymes are also able to catalyze other reactions that 
were typically considered to be strictly limited to small molecule catalysis. This is 
the case in the allylic alkylation of 1,3-diphenylallyl acetate 35 (Figure 17).55 It is 
well known that soft nucleophiles directly attack the η3-bound allyl moiety rather 
than proceeding through metal coordination followed by reductive elimination. 
Ward found that combining a biotinylated bis-phosphine ligand with a palladium 
catalyst, the allylation occurs in high yield in modest selectivity. The mutant 
S112A provided the alkylated product 37 in excellent enantioselecitivity. A single 
mutation S112Q afforded the opposite (R)-37 in 31 % ee. Introduction of an 
enantiopure (R)-proline spacer between the biotin anchor and the palladium 
complex, combined with the double mutant S112G V47G, lead to an increase in 
enantioselectivity in favor of the (R)-enantiomer (up to 82% ee (R)).  
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Figure 17 An artificial allylic allylase based on the biotin-streptavidin technology. 
  
Streptavidin-based artificial metalloenzymes can also be effective 
catalysts for enantioselective Suzuki reactions that form atropisomers (Figure 
18). As a model reaction, 1-iodo naphthalene was coupled to 2-methoxy-1-
naphthalene boronic acid. After screen a small library of monodentate 
biotinylated ligands, it was found that electron-rich di-tert-butyl phosphines 
provided the best yield. A screen of single mutants at position S112 and K121 
revealed modest enantioselectivities for K121E (76% ee R). When this mutation 
was coupled with mutants at position S112 or N118, a mutant capable of 
providing quantitative yield and 90% ee was achieved with S112Y-K121E. This 
hybrid catalyst is effective toward a variety of aryl iodides in excellent yield.56   
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Figure 18 An artificial Suzukiase based on the biotin-streptavidin technology. 
Two point mutations improve the enantioselectivity from 58 % to 90 %. 
 
3.2 Human Carbonic Anhydrase 
 Human carbonic anhydrase is responsible for the reversible conversion of 
CO2 to bicarbonate.57 Sulfonamides are known to inhibit this activity through 
coordination of the sulfonamide’s nitrogen to the catalytically active zinc. Ward 
prepared a family of amino-pyridine and sulfonamide-pyridine ligands covalently 
linked to p-arylsulfonamides and tested their ability to effect transfer 
hydrogenation of imines. The best results were observed with the sulfonamide-
pyridine ligand although mutagenesis of the flanking residues failed to provide 
increased yields or enantioselectivity (55 TON, 32 % ee, Figure 19). The X-ray 
crystal structure of the artificial imine reductase revealed only a partial occupancy 
of the pianostool moiety within the funnel-shaped hCAII binding site. The authors 
speculated that this may be caused by the shallow potential energy surface due 
to the lack of stabilizing interactions between the pianostool and the host protein. 
In collaboration with the Baker group, in silico screening lead to the identification 
of up to eight mutations (L60V-A65T-N67W-E69Y-Q92F-L140M-L197M-C205S) 
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predicted to improve the cofactor · hCAII interactions.58 These mutants were 
expressed and tested for their affinity towards the sulfonamide bearing cofactor. 
Gratifyingly, both the affinity, the activity and the selectivity were significantly 
improved compared the the WT hCA II, providing product in 92% ee (Figure 19). 
 
Figure 19 Artificial imine reductase based on the sulfonamide-carbonic 
anhydrase couple. In silico screening lead to the identification of critical residues, 
ultimately allowing to significantly improve the affinity, the activity and the 
enantioselectivity of the iridium-based hybrid. 
 
4. Covalent Anchoring 
4.1 LmrR-Based Metalloenzymes 
Roelfes and coworkers proposed that the hydrophobic pore of the 
transcriptional repressor from L. lactis (LmrR) might provide an effective 
environment for the generation of artificial metalloenzymes.59 They thus selected 
LmrR, which in its dimeric form, generates a flat hydrophobic pore to host 
artificial metal cofactors. By introduction of a cysteine residue into the 
hydrophobic active site, a Cu(II) phenanthroline moiety was bioconjugated into 
the hydrophobic pore. Initially, the complex was tested on the copper-catalyzed 
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Diels-Alder reaction between ketone 41 and cyclopentadiene. Under optimized 
conditions, the metalloenzyme provided product in excellent conversion, high 
endo selectivity, and excellent enantioselectivity. Upon mutation of the flanking 
valine residue to alanine (V15A) the endo:exo selectivity increased with little loss 
in conversion or enantioselectivity. This scaffold was also applied to a copper-
catalyzed oxa-Michael addition, but flanking mutations failed to provide any 
increase in selectivity or yield.60 
 In these first-generation reports, Roelfes took advantage of bioconjugating 
of the ligand into the active site to localize the metal in the hydrophobic pore. The 
disadvantage to this approach is the addition of a step to prepare the catalyst. An 
alternative approach is to genetically engineer a non-natural amino acid with a 
side chain capable of ligating to the metal. Using AMBER codon suppression and 
a bipyridyl-alanine amino acid, Roelfes generated an artificial metalloenzyme 
capable of catalyzing a vinylogous Friedel-Crafts reaction between a Michael 
acceptor and indole in modest yield.61 Screening various mutations in the active 
site provided a variant, M89X-E107A, that provided product in 66% ee. The 
overall conversion could be increased to 58% by adding an addition mutation, 
M89X-N19A-E107A, but at the cost of enantioselectivity (14% ee).  
–37– 
 
Figure 20. Relying on the LmR as host protein, Roelfes et al. engineered either a 
phenanthroline, via bioconjucation or a bipyridylalanine using the AMBER codon 
suppression technology. The resulting ArM catalyzes the Diels-Alder 
cycloaddition and the asymmetric Friedel-Crafts alkylation. 
 
4.2 Prolyl Oligopeptidase 
 Typically, metal cofactors in artificial metalloenzymes reside near the 
surface of the protein of choice. While this can be effective for selective catalysis, 
a metal in a more enclosed active-site could provide a more selective catalyst. 
Lewis pioneered covalently linking metal cofactors to proteins using strain-
promoted azide-alkyne cycloadditions, where L-4-azidophenylalanine was 
genetically introduced using AMBER codon suppression (Figure 21a).62 Lewis 
found that a Rh(II)-dimer can be introduced into the active site of prolyl 
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oligopeptidase from Pyrococcus furiosus by mutation of the non-natural amino 
acid residue at position 477 (Z477), and expanding the active site by introduction 
of alanine at four positions (E104, F146, K199, and D202).63  The resulting 
protein, containing 5 mutations, was able to effect cyclopropanation of styrene 
with donor-acceptor diazoesters in modest yield and enantioselectivity. When 
histidine was introduced in the active site at position 328 (H328), presumably to 
decrease conformational freedom and to block one rhodium center, the 
enantioselectivity increased to 47% ee with modest yield. Introduction of 
phenylalanine residues in the activity site (F99-F594 or F99, F97) further 
optimizes the reaction to 74% yield and 92% ee. It is interesting to note that 
these mutation also substantially decrease the degree of diazo hydrolysis for 2:1 
favoring hydrolysis with the 4-alanine mutations, to ~5:1 favoring 
cyclopropanation over hydrolysis with the best variant.  
–39– 
 
 
Figure 21. Evolutionary history for the genetically optimized artificial 
cyclopropanase using prolyl oligopeptidase from Pyrococcus furiosus (POP) as 
host protein.  
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5. Artificial Hydrolases 
Metallohydrolyases are ubiquitous in nature serving various roles in 
cellular metabolism. There are numerous classes that rely on different metals to 
effect the desired transformations. Kim and coworkers set out to develop a new 
β-lactamase from a glyoxalase.64 These enzymes differ both in the metal cofactor 
and in the nature of the active site. Kim used a three step approach to develop 
this new enzyme. The first was to remove the C-terminal domain required for 
substrate recognition in the glyoxylase II. Following this step, the enzyme’s 
activity towards the natural substrate was completely suppressed. The second 
step was to introduce mutations to increase the affinity for zinc. This was 
achieved by introducing two cysteine residues as well as a tyrosine and an 
aspartic acid to stabilize zinc binding. Finally, a new loop was introduced based 
on sequence alignment with other metallo-betalactamases. In the final step, a 
number of residues were randomized to allow for fine tuning toward the selected 
β-lactam substrates. After screening 2.1 x 107 mutants, 13 positive variants were 
identified. The best variant had most of the mutations in the substrate binding 
domain. 
One could imagine generating a completely new protein fold to generate 
artificial metalloenzymes. This is particularly challenging in view of the difficulty of 
predicting tertiary and quaternary protein structures. Tezcan has predicted, 
confirmed and exploited the generation of quaternary structures exploiting metal 
–41– 
coordination (Figure 22).65 In the course of these studies, metal binding were 
used for creating and maintaining the quaternary structure, while others served 
as catalysts. In the artificial folds generated from zinc and cb562 (a heme 
containing four helix bundle), when a flanking lysine residues is mutated to 
alanine, appreciable activity was observed on p-nitrophenylacetate and 
ampicilline. Mutation of residues proximal to the catalytically active zinc-binding 
site provided a mutant with superior activity. 
 
 
Figure 22 Artificial metallohydrolase resulting from supramolecular assembly 
(PDB 4U9D). 
Metalloproteins that lack any catalytic function can be rendered 
catalytically active using directed evolution. Starting from a retinoid-X-receptor 
protein, Szostak and Seelig found that through randomization of the two of the 
loops found in the zinc-finger domain of the protein can induce RNA-ligase 
activity.66 To achieve this feat, an in vitro selection based on mRNA-display was 
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employed.  In these studies, the coding mRNA was covalently linked to its coded 
protein. Reverse-transcription with a modified primer links the substrate to the 
protein/mRNA catalyst. Upon treatment with a short RNA-fragment and a 
biotinylated RNA-fragment, proteins that are capable of catalyzing the reaction 
ligate the biotinylated fragment to the reverse transcription fragment. Upon 
selection and amplification, the best catalyst can be identified. After 17 rounds of 
directed evolution, an RNA-ligase was produced that provided a catalyst with 
multiple catalyst turnovers and a two million-fold enhancement over the starting 
complex. This unique approach highlights the potential for achieving completely 
new reactivity.   
Computational design has also be used to reappropriate enzyme function. 
Baker and coworkers used computation to repurpose the zinc containing mouse 
adenosine deaminase into an organophosphate hydrolysase (Figure 23). A 
search of the protein database (PDB) for proteins that contain zinc centers with 
one open coordination site coupled with rosetta design to reshape an active site 
to fit the geometry of the substrate provided 12 different designed proteins. Of the 
12, six constructs were expressed as soluble proteins, but only one provided the 
desired reactivity. To further optimize the reactivity, 12 positions near the active 
site were mutated, including five that were identified via computational design. 
These twelve site-saturation libraries provided three improved mutants. 
Combining these mutations afforded a mutant with a 40 fold increased activity 
over the parent construct. An additional round of error-prone pcr lead to the 
–43– 
identification of three additional mutations. A final round of site saturation 
mutagenesis provided a variant with over 2500 fold improvement over the parent 
protein. A comparison of the crystal structure with the computational model 
confirmed the exquisite predictive power (including side chain orientation) of the 
rosetta design. 
 
Figure 23 Artificial metallophosphatase resulting from computational design 
combined with directed evolution. 
6. Outlook    
Recent advances by Arnold and Fasan suggest a bright future for repurposing 
existing metalloprotein function to catalyze synthetically useful, new-to-nature 
reactions. These heme-containing enzymes have evolved to function in a cellular 
environment; the repurposed enzymes can thus be screened either in vivo or in 
the presence of cell lysates. For directed evolution purposes, this represents a 
major asset as this significantly speeds up the optimization process. The same 
holds true for the Zn-containing artificial hydrolases which have been evolved 
without the need to rigorously purify the protein samples.64, 65, 66 
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In stark contrast, most abiotic metal-containing cofactors are inhibited in the 
presence of cellular extracts. This nuisance also severely limits the use of 
transition metal catalysts for chemical biology applications. 67  Interestingly, 
dirhodium-tetracarboxylate motifs have been shown maintain their catalytic 
function in cell lysates.68 This feature has been beautifully exploited by Lewis to 
evolve an artificial cyclopropanase (Figure 21). This represents a rare example of 
a biocompatible precious metal catalyst.69 Alternatively, the chemical reagents 
(Michael acceptors or oxidants) have been exploited to neutralize inhibitors, 
enabling the screening of an [Cp*Ir(biot-p-L)Cl] in the presence of cell lysates 
(Figure 12).12 Affinity tags or chromatography may be exploited for the parallel 
purification of host proteins.42, 44 
In our view, the future of artificial metalloenzymes lies primarily in the area of 
synthetic biology rather than in white biotechnology applications. Indeed, 
complementing metabolic pathways with the catalytic power of abiotic metal 
cofactors in vivo, may open fascinating perspectives for the synthesis of biofuels 
or high-added value products. To realize this however, several challenges 
remain: i) cofactor uptake in vivo; ii) efficient cofactor bioconjugation and iii) in 
vivo cascade reactions combining ArMs and natural enzymes. 																																																								
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